Novartis
Strong results for Novartis drug in rare autoimmune disease
October 30, 2008Research and Development, Sales and Marketing Novartis
Novartis' development drug ACZ885 (canakinumab) has turned in impressive results in trials for rare medical conditions. It showed sustained remission …
Novartis appoints Reinhardt as chief operating officer
October 24, 2008Sales and Marketing Novartis
Novartis has shaken up its senior management structure with the creation of a new post – chief operating officer. From …
Osteoporosis drug Aclasta approved for use in men
October 2, 2008Sales and Marketing Novartis, aclasta, osteoporosis
Osteoporosis treatment Aclasta has been approved for an extended indication in the European Union.Novartis’ once-yearly infusion has now been given …
Novartis’ European chief says ‘Geotailoring’ will speed decision making and bring it closer to customers
January 28, 2008Sales and Marketing Eric Cornut, Novartis
Q: Europe’s biggest market Germany is preparing for some major reforms at the moment. How is Novartis responding to that …
Jimenez aims for savings and marketing rejuvenation
January 28, 2008Sales and Marketing Jimenez, Jiminez, Novartis
The head of Novartis’ pharmaceutical business Joe Jimenez has set out his plans to make the division more efficient and …
Novartis changes pharma management after weak third quarter
October 19, 2007Sales and Marketing Novartis
Novartis has switched the heads of its consumer and pharmaceuticals divisions as part of a wider reorganisation of its pharma …
Indian court dismisses Novartis patent claim
August 8, 2007Sales and Marketing India, Novartis
Novartis has failed in its challenge to India's intellectual property laws as part of its attempt to secure a patent …
Latest news from Datamonitor
June 22, 2007Research and Development, Sales and Marketing NSCLC, Novartis, Pfizer
Novartis receives FDA approval for blood pressure medicineNovartis has been granted final FDA approval for Exforge, its high blood pressure …
Lucentis approved in Europe
January 26, 2007Sales and Marketing Lucentis, Novartis
European regulators have approved Novartis’ Lucentis, a new treatment for neovascular age-related macular degeneration, known as wet AMD.The company says …
New blindness treatment moves closer to market
November 28, 2006Sales and Marketing AMD, Lucentis, Novartis
Patients suffering from the leading cause of blindness could soon benefit from a new treatment after it gained preliminary approval …
Novartis to be first pharma to conduct R&D in China
November 7, 2006Research and Development Asia, China, Novartis, em
Novartis is to open a major, new pharmaceutical research and development centre in China, becoming the first company in the …
New Novartis blindness treatment filed in Europe
March 2, 2006Sales and Marketing AMD, Lucentis, Novartis
Lucentis, a new treatment for neovascular age-related macular degeneration or ‘wet AMD’ has been submitted by Novartis to the European …
Next generation monoclonal antibodies to enter clinical trials in 2007
January 20, 2006Research and Development Ablynx, Novartis
Novartis has signed a deal with Belgium biotech Ablynx to develop the next generation of monoclonal antibodies with clinical development …
Latest content
FibroFind appoints Lee Borthwick as CEO
